WO2007072491A3 - Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same - Google Patents
Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same Download PDFInfo
- Publication number
- WO2007072491A3 WO2007072491A3 PCT/IN2005/000425 IN2005000425W WO2007072491A3 WO 2007072491 A3 WO2007072491 A3 WO 2007072491A3 IN 2005000425 W IN2005000425 W IN 2005000425W WO 2007072491 A3 WO2007072491 A3 WO 2007072491A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- 17beta
- estradiol
- heart disease
- coronary
- micro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
Abstract
This invention relates to a method of treating ischemic heart disease by stimulating arteriogenesis and angiogenesis. This is achieved by intracoronary administration of a sustained release pharmaceutical formulation containing 17beta-estradiol microencapsulated in biodegradable polymers. A method for stimulation of arteriogenesis and angiogenesis in severe ischemic heart disease by the intra-coronary administration of 17beta-estradiol is described. The 17beta-estradiol is delivered preferably in the form of encapsulated bio-degradable micro-spheres. Intra-coronary delivery of 17beta-estradiol - loaded microspheres can be easily performed during the procedure of cardiac catheterization. The administered 17beta-estradiol - loaded micro-spheres become trapped in the coronary micro-circulation, and undergo gradual degradation producing a sustained concentration of 17beta-estradiol at the level of coronary micro-circulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2005/000425 WO2007072491A2 (en) | 2005-12-21 | 2005-12-21 | Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2005/000425 WO2007072491A2 (en) | 2005-12-21 | 2005-12-21 | Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007072491A2 WO2007072491A2 (en) | 2007-06-28 |
WO2007072491A3 true WO2007072491A3 (en) | 2007-11-08 |
Family
ID=38189081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2005/000425 WO2007072491A2 (en) | 2005-12-21 | 2005-12-21 | Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007072491A2 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643604A (en) * | 1990-06-14 | 1997-07-01 | Aplicaciones Farmaceuticas S.A. De C.V. | Parenteral dosage form |
US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
-
2005
- 2005-12-21 WO PCT/IN2005/000425 patent/WO2007072491A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6309669B1 (en) * | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US5643604A (en) * | 1990-06-14 | 1997-07-01 | Aplicaciones Farmaceuticas S.A. De C.V. | Parenteral dosage form |
US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
Also Published As
Publication number | Publication date |
---|---|
WO2007072491A2 (en) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Simos et al. | Trends of nanotechnology in type 2 diabetes mellitus treatment | |
Jamaledin et al. | Engineered microneedle patches for controlled release of active compounds: recent advances in release profile tuning | |
JP5159303B2 (en) | Controlled release composition | |
JP5881606B2 (en) | Preparation for spinal cord injury treatment | |
JP5306599B2 (en) | Long-term delivery formulation | |
US9498431B2 (en) | Controlled releasing composition | |
ES2384641T3 (en) | Lipolytic formulation that enhances the release maintained for the localized treatment of adipose tissue | |
US9597436B2 (en) | Advanced heart failure treatment material as myocardial/cardiovascular regeneration device | |
JP5628467B2 (en) | Biodegradable sustained release drug delivery system | |
Shipton | New formulations of local anaesthetics—Part I | |
KR20130114240A (en) | Nanoparticles loaded with chemotherapeutic antitumoral drug | |
HUE026994T2 (en) | Liquid nasal spray containing low-dose naltrexone | |
KR20210077697A (en) | Coatings for endoluminal expandable catheters providing contact delivery of drug micro-reservoirs | |
Angamuthu et al. | Controlled-release injectable containing Terbinafine/PLGA microspheres for Onychomycosis Treatment | |
WO2009116556A1 (en) | Pharmaceutical composition for injection | |
CN104027793A (en) | Preparation method and application of nerve growth factor controlled-release nano-carrier | |
RU2010110658A (en) | COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC DISEASES | |
WO2004006929A1 (en) | Composition for nasal absorption | |
US20210275536A1 (en) | Appetite suppressant compositions and methods thereof | |
CA2958195A1 (en) | Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same | |
WO2007072491A3 (en) | Sustained release pharmaceutical formulation and treatment of ischemic heart disease by administering the same | |
JP2011519946A (en) | 1-methylnicotinamide analogues | |
KR20170032801A (en) | Soluble microneedle patch for delivery of atopic dermatitis drug | |
CN111148512A (en) | Delivery pharmaceutical composition comprising a penetration enhancer | |
Yao et al. | Nano-particle engineered atorvastatin delivery to support mesenchymal stem cell survival in infarcted myocardium |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05849953 Country of ref document: EP Kind code of ref document: A2 |